Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 18:10:2482.
doi: 10.3389/fimmu.2019.02482. eCollection 2019.

Refractory Anaphylaxis: Data From the European Anaphylaxis Registry

Affiliations

Refractory Anaphylaxis: Data From the European Anaphylaxis Registry

Wojciech Francuzik et al. Front Immunol. .

Abstract

Refractory anaphylaxis (unresponsive to treatment with at least two doses of minimum 300 μg adrenaline) is a rare and often fatal hypersensitivity reaction. Comprehensive data on its definition, prevalence, and risk factors are missing. Using the data from the European Anaphylaxis Registry (11,596 cases in total) we identified refractory anaphylaxis cases (n = 42) and analyzed these in comparison to a control group of severe anaphylaxis cases (n = 4,820). The data show that drugs more frequently elicited refractory anaphylaxis (50% of cases, p < 0.0001) compared to other severe anaphylaxis cases (19.7%). Cases elicited by insects (n = 8) were more often due to bees than wasps in refractory cases (62.5 vs. 19.4%, p = 0.009). The refractory cases occurred mostly in a perioperative setting (45.2 vs. 9.05, p < 0.0001). Intramuscular adrenaline (as a first line therapy) was administered in 16.7% of refractory cases, whereas in 83.3% of cases it was applied intravenously (significantly more often than in severe anaphylaxis cases: 12.3%, p < 0.0001). Second line treatment options (e.g., vasopression with dopamine, methylene blue, glucagon) were not used at all for the treatment of refractory cases. The mortality rate in refractory anaphylaxis was significantly higher (26.2%) than in severe cases (0.353%, p < 0.0001). Refractory anaphylaxis is associated with drug-induced anaphylaxis in particular if allergens are given intravenously. Although physicians frequently use adrenaline in cases of perioperative anaphylaxis, not all patients are responding to treatment. Whether a delay in recognition of anaphylaxis is responsible for the refractory case or whether these cases are due to an overflow with mast cell activating substances-requires further studies. Reasons for the low use of second-line medication (i.e., methylene blue or dopamine) in refractory cases are unknown, but their use might improve the outcome of severe refractory anaphylaxis cases.

Keywords: adrenaline (epinephrine); anaphylaxis; beta-blockers; drug allergic reactions; insect venom allergy; refractory; vasoconstriction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart illustrating the cases selection process for the final database.
Figure 2
Figure 2
Visual representation of the three forces determining the severity of anaphylaxis. The natural ability of the body to compensate for the anaphylaxis symptoms and therapeutic measures acting to restore homeostasis. Elicitors and cofactors influence the severity of a given episode synergistically.

References

    1. Simons FE, Sampson HA. Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years). J Allergy Clin Immunol. (2015) 135:1125–31. 10.1016/j.jaci.2014.09.014 - DOI - PubMed
    1. Grabenhenrich LB, Dölle S, Ruëff F, Renaudin JM, Scherer K, Pföhler C, et al. . Epinephrine in severe allergic reactions: the european anaphylaxis register. J Allergy Clin Immunol. (2018) 6:1898–906. 10.1016/j.jaip.2018.02.026 - DOI - PubMed
    1. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. . Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. Ann Emerg Med. (2006) 47:373–80. 10.1016/j.annemergmed.2006.01.018 - DOI - PubMed
    1. Francuzik W, Dölle S, Worm M. Risk factors and treatment of refractory anaphylaxis-a review of case reports. Expert Rev Clin Immunol. (2018) 14:307–14. 10.1080/1744666X.2018.1450140 - DOI - PubMed
    1. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. . Anaphylaxis in children and adolescents: the European anaphylaxis registry. J Allergy Clin Immunol. (2016) 137:1128–37.e1. 10.1016/j.jaci.2015.11.015 - DOI - PubMed

Publication types